From their first moments through their later years, we exist for one purpose—to help our patients live better, fuller lives.
AlanAmplatzer™ Talisman™ PFO Occluder
“It’s scary,” said Alan, who had had a stroke due to a patent foramen ovale, and who didn’t know if or when he might have a recurrent stroke. After Amplatzer™ PFO closure, “he’s like a new man,” his wife, Emma, remarked about Alan, who’s back to walking 12 miles a day as a mail carrier. “And I owe everyone a massive thank you,” Alan said.
JozefAmplatzerTM VSD Occluder
Over time Jozef’s ventricular septal defect (VSD) precipitated endocarditis which in turn led to heart failure and kidney failure. After receiving the Amplatzer™ VSD Occluder Jozef, amazed at his energy and ability to walk long distances again, said “I feel joy deep inside me—inside my heart.”
These testimonials relate to accounts of individuals’ responses to treatments. The patients’ accounts are genuine, typical, and documented. However, it does
not provide any indication, guide, warranty, or guarantee as to the response other persons may have to a treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient.
In the 2022 AHA/ACC/HFSA Heart Failure Guideline2, TEER has been strengthened to a Class 2a recommendation for COAPT-like* secondary MR patients, reinforcing the 2020 Valvular Heart Disease Guideline3.
†Secondary MR patients despite optimal GDMT.
*COAPT-like: NYHA II-IV; severe secondary MR; suitable anatomy; LVEF 20%-50%; LVESD≤70mm; PASP≤70mm HG.
MAT-2008871 v5.0 | Item approved for U.S. use only.